Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 7

1.

DL-3-n-butylphthalide delays the onset and progression of diabetic cataract by inhibiting oxidative stress in rat diabetic model.

Wang F, Ma J, Han F, Guo X, Meng L, Sun Y, Jin C, Duan H, Li H, Peng Y.

Sci Rep. 2016 Jan 13;6:19396. doi: 10.1038/srep19396.

2.

A simple and stable galactosemic cataract model for rats.

Ji L, Li C, Shen N, Huan Y, Liu Q, Liu S, Shen Z.

Int J Clin Exp Med. 2015 Aug 15;8(8):12874-81. eCollection 2015.

3.

Role of Cytochrome Modulators in Altering the Occurrence of Cataract in Rats.

Gupta K, Juneja S, Bajwa GS, Kaushal S.

J Clin Diagn Res. 2015 Jul;9(7):FF05-7. doi: 10.7860/JCDR/2015/12411.6216. Epub 2015 Jul 1.

4.

Targeting CYP450 modulation to decrease the risk of induced cataract in the experimental model.

Patel DV, Gandhi TR, Patel KV, Patil DB, Parikh PV.

Indian J Ophthalmol. 2010 Nov-Dec;58(6):471-5. doi: 10.4103/0301-4738.71676.

5.

Oxidative damage and the prevention of age-related cataracts.

Beebe DC, Holekamp NM, Shui YB.

Ophthalmic Res. 2010;44(3):155-65. doi: 10.1159/000316481. Epub 2010 Sep 9. Review.

6.

Diabetic cataract-pathogenesis, epidemiology and treatment.

Pollreisz A, Schmidt-Erfurth U.

J Ophthalmol. 2010;2010:608751. doi: 10.1155/2010/608751. Epub 2010 Jun 17.

7.

Erythrocyte aldose reductase activity and sorbitol levels in diabetic retinopathy.

Reddy GB, Satyanarayana A, Balakrishna N, Ayyagari R, Padma M, Viswanath K, Petrash JM.

Mol Vis. 2008 Mar 24;14:593-601.

Items per page

Supplemental Content

Write to the Help Desk